Xtant Medical (XTNT) Q3 2026 earnings review

Xtant Medical grows biologics sales, but its board pulls targets

Xtant Medical, a maker of bone grafts and spinal implants, pulled its full-year plan and started a strategic review as sales missed its own target again. Biologics revenue rose 11% from last quarter to $19 million, lifted by HEMOBLAST bleeding-control powder and a larger sales team. However, shrinking hardware sales held total revenue to $24 million, and cash dropped to $8 million.

At a glance
Revenue from continuing products+8.6% from a year ago by our math (reported: -27%)
Biologics revenue$19.3M +13% from a year ago (+11% from last quarter)
Gross margin56.3% 66.1% a year ago (57.9% last quarter)
Full-year revenue outlookWithdrawn prior plan: $99M to $103M

โš–๏ธ Verdict: ๐Ÿ”ด Bearish

The story got worse because the board abandoned its full-year revenue target, canceled the earnings call, and put restructurings, financings, and asset sales on the table. Board chairman Stavros Vizirgianakis called missing the company's own plan for a second straight quarter "unacceptable". One bright spot: core bone-graft sales excluding HEMOBLAST and wound-care items grew 8% from last quarter.

The question now is whether the board can fix the cash burn through cost cuts or must raise money and sell assets on tough terms. Either growing biologics sales will cover the newly hired sales reps, or low gross margins and debt rules will force a restructuring. The third-quarter regulatory filing and the board's review will decide.

๐Ÿ‚ Bull Case

๐ŸŸข strengthening GROWTH

Core Biologics Grew Without Relying on HEMOBLAST

Xtant Medical sells orthobiologics, which are human tissue and synthetic grafts that help bones heal after surgery. Board chairman Stavros Vizirgianakis said: "Already we are encouraged by how our core biologics business is gaining momentum both quarter-over-quarter and year-over-year." Total biologics sales rose 13% from a year ago and 11% from last quarter to $19.3 million.

That growth did not just come from newly added products. Excluding HEMOBLAST, a surgical bleeding-control powder, and wound-care products hurt by Medicare rules, underlying biologics sales still rose 8% from last quarter and 6% from a year ago to $17.1 million. The expanded field sales team is starting to move the core surgical graft line.

What to watch: fourth-quarter underlying biologics revenue excluding HEMOBLAST and wound-care items. Another sequential rise above $17.1 million would show the larger sales force can grow the core business on its own.

๐ŸŸข strengthening PRODUCT

HEMOBLAST Sales Stepped Up as Reps Integrated

In April 2026, the spinal surgery supplier took over exclusive US distribution for HEMOBLAST Bellows, a powder from Dilon Technologies that stops bleeding during operations, and hired about 20 Dilon sales reps. Management wanted those specialists to sell both HEMOBLAST and Xtant Medical's bone grafts.

HEMOBLAST contributed $2.2 million to third-quarter revenue, up 69% from the $1.3 million booked in the second quarter as more customer orders moved onto Xtant Medical's own contracts. The product accounted for $0.9 million of the $2.0 million sequential increase in total biologics revenue, though it remained slightly below the $2.5 million quarterly pace management's earlier monthly volume comments pointed to.

What to watch: fourth-quarter HEMOBLAST sales and the revenue note in the quarterly filing. A climb toward $3 million would show the transition from Dilon-fulfilled orders to direct sales is complete.

๐Ÿป Bear Case

๐Ÿ”ด๐Ÿ”ด new GOVERNANCE contradicts narrative

Board Pulled the Plan and Started a Review

"The Board is disappointed with Xtantโ€™s financial performance this quarter, which marks the second consecutive quarter in which our results have not met our guidance. That is unacceptable," board chairman Stavros Vizirgianakis said. Chief executive Sean Browne did not appear in the release, and the Montana medical device maker canceled its quarterly conference call.

The company withdrew its full-year revenue outlook of $99 million to $103 million and launched a board-led review covering "restructurings, financings, acquisitions, dispositions, business combinations or other transactions". Even though Vizirgianakis praised momentum in core biologics, total third-quarter sales of $24.3 million fell 15% short of the $28.5 million quarterly pace that the old full-year plan required by our math.

What to watch: any board announcement on financing, asset sales, or leadership in upcoming regulatory filings. A dilutive capital raise or forced asset sale would confirm that cash pressure drove the review.

๐Ÿ”ด๐Ÿ”ด persistent CASH

Cash Burn Continues as Margin Stays Low

Xtant Medical previously aimed for positive free cash flow in 2026 and a gross margin in the low-60% range. Instead, third-quarter gross margin fell to 56.3% from 66.1% a year ago and 57.9% in the second quarter, while the company burned cash for a third straight quarter.

  • Total cash including restricted cash: $7.9 million, down from $10.2 million in June and $17.3 million in December
  • Third-quarter free cash flow: negative $1.2 million by our math, bringing nine-month cash burn to $11.1 million
  • Cost of making products: 43.7% of sales, up 9.9 percentage points from a year ago, hurt by $1.4 million of inventory write-downs in the quarter by our math
  • Sales and marketing costs: 46.0% of sales, up 10.7 percentage points from a year ago after hiring the Dilon sales team

This matters because losing the high-margin licensing stream left Xtant Medical with too much overhead and factory cost for its current sales base. The company still expects its $7.8 million in unrestricted cash and $2.1 million in credit line availability to fund operations for at least 12 months.

What to watch: fourth-quarter operating cash flow and unrestricted cash at year-end. Another cash drop of more than $1 million would shrink the buffer further before any restructuring takes effect.

๐Ÿ”ด persistent GROWTH

Spinal Hardware Keeps Shrinking After Asset Sales

Alongside bone grafts, Xtant Medical sells metal spinal implants for back surgeries. Late last year it sold its Coflex and CoFix implant lines and its international hardware business to Companion Spine so it could focus on biologics, leaving a smaller US spinal hardware line.

Reported hardware revenue dropped 53% from a year ago to $4.9 million. Even after stripping out the $5.4 million of divested revenue from last year's third quarter, underlying hardware sales fell 5.3% from a year ago by our math and dropped 12.8% from the second quarter's $5.7 million. That $0.7 million sequential drop erased more than a third of the gains made in biologics.

What to watch: fourth-quarter spinal hardware revenue. A drop below $4.5 million would show the remaining US implant lines are still losing surgeons while the board weighs selling more assets.

๐Ÿ”ด persistent DISCLOSURE

Risks this quarter didn't answer

Because Xtant Medical canceled its earnings call and has not yet provided the full quarterly filing notes in this release, three standing risks received no new numbers.

  • HEMOBLAST supply past September: last quarter's filing warned supply from Dilon was only assured through the third quarter; the new release lists Dilon supply in its risk factors without stating fourth-quarter inventory levels.
  • Debt covenant headroom: the company needed waivers on its minimum revenue covenant in two of the prior three quarters; the quarterly filing's debt note will show whether the third-quarter revenue miss triggered another amendment.
  • Aging bone graft lines: management did not split core biologics between older demineralized bone matrix products and newer launches like Trivium and CollagenX.

๐Ÿ‘“ Other Themes

persistent MACRO

Medicare Rules Wiped Out Licensing Revenue

Changes to Medicare wound-care reimbursement rules ended Xtant Medical's high-margin amniotic membrane licensing deals at the close of 2025. Licensing brought in zero revenue this quarter versus $5.5 million a year ago, which cut 6.7 percentage points from gross margin and explains why reported total sales fell 27% despite underlying product growth of 8.6% by our math.

๐Ÿ’ฒ Other KPIs

Total debt and credit line (26Q3) $22.0 million
โ‡˜ decelerating

Total debt fell from $23.0 million in June and $25.4 million at the end of 2025 as the spinal device maker paid down its term loan. Borrowings on the revolving credit line stood at $11.8 million, while remaining borrowing availability rose to $2.1 million from $0.7 million last quarter.

General and administrative expenses (26Q3) $5.0 million
โ‡˜ decelerating

Overhead costs dropped 29.1% from $7.1 million a year ago and fell 22.1% from $6.4 million in the second quarter. The orthobiologics group cut administrative spending by shedding its international hardware operations and paying less under employee bonus plans, bringing overhead down to 20.6% of revenue.

Diluted share count (26Q3) 140.4 million
โ‡˜ decelerating

Diluted shares used to calculate per-share earnings fell 6.7% from 150.4 million a year ago. Because the business recorded a net loss of $3.6 million this quarter versus a $1.3 million profit last year, stock options and warrants are excluded from the count while basic shares ticked up 0.5%.

๐Ÿ”ฎ Guidance

FY26 Revenue Withdrawn
โœ• withdrawn, was $99.0โ€“103.0 million
โ‡˜ decelerating

Withdrawn. Xtant Medical said it "no longer expects to achieve its previously issued full-year 2026 guidance" and gave no replacement while the board conducts its strategic review. By our math, hitting the middle of the old $99 million to $103 million target would have required $32.8 million of fourth-quarter revenue, a 35% jump from the third quarter. Management had raised the target in May before cutting it in August.

โ“ Key Questions

Did Dilon extend HEMOBLAST supply beyond the third quarter?

Last quarter's filing warned that HEMOBLAST supply from Dilon Technologies was only assured through September 30, 2026. Investors need to know whether Xtant Medical has enough inventory on hand to keep growing its $2.2 million quarterly HEMOBLAST sales in the fourth quarter.

Did the third-quarter revenue shortfall trigger a debt covenant breach?

Xtant Medical needed lender waivers on its minimum net revenue covenant in two of the prior three quarters. Because third-quarter revenue missed the company's own plan again, the upcoming quarterly filing must show whether lenders required another waiver or faster debt repayment.

Why did chief executive Sean Browne not comment this quarter?

Board chairman Stavros Vizirgianakis delivered the entire executive quote in the release, called two straight missed quarters unacceptable, and canceled the earnings call. Shareholders need clarity on whether a leadership change is part of the board's operational review.

What is choking off gross margin besides lost licensing sales?

Even without licensing revenue in either period, gross margin fell 1.6 percentage points from the second quarter to 56.3%, and inventory write-downs hit $1.4 million by our math. Management has not explained which product lines are causing the ongoing inventory obsolescence.